# Portable eye-tracking in neurology: current uses and future perspectives in cognition

## TL;DR

Portable eye-tracking devices are being used in neurology to study cognitive disorders and could help diagnose and monitor conditions like Alzheimer's and Parkinson's.

## Contribution

This systematic review evaluates the clinical reliability and current applications of portable eye-tracking devices in neurological assessments.

## Key findings

- Portable eye-tracking devices like Neurolign DX 100 and Tobii show precision in detecting cognitive impairments.
- Advancements in device accuracy and accessibility improve detection of subtle cognitive changes through eye movements.
- These devices are promising for early diagnosis and monitoring of neurological diseases like multiple sclerosis.

## Abstract

Eye tracking technology has emerged as a pivotal tool in neurology, providing objective insights into ocular motor function and cognitive processes across various neurological conditions, including mild traumatic brain injury, autism spectrum disorder, schizophrenia, attention deficit hyperactivity disorder, and neurodegenerative diseases like Alzheimer's and Parkinson's disease.

The present systematic review evaluates the current applications and reliability of portable eye-tracking devices in clinical practice, highlighting their transformative potential for diagnosing and monitoring cognitive disorders.

A systematic review was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Observational studies using portable eye-tracking devices were included. Databases searched included PubMed, Embase, and Cochrane, with studies screened and reviewed by two independent authors. Outcomes assessed were eye movements and visual responses in neurological patients. The Critical Appraisal Skills Program (CASP) checklist was used to assess study quality and bias.

A total of 62 studies were identified, with 27 included after screening. The findings reveal significant advancements in device accessibility, sampling rates, and accuracy, which enhance the ability to detect subtle cognitive changes through eye movement patterns. Portable devices such as Neurolign DX 100 (Neurolign USA, LLC) and Tobii (Tobii), which is a portable video-oculography (VOG) devices including Neurolign DX 100 and Tobii systems, were highlighted for their precision and applicability in clinical settings.

Portable eye-tracking devices show promise for detecting cognitive impairments in neurological conditions like multiple sclerosis. Their portability and ease of use facilitate widespread clinical application, making cognitive assessments more accessible and effective in early diagnosis and monitoring of disease progression.